Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride augmentation of escitalopram for faster antidepressant response in major depressive episode
2025-521811-38-01Phase 2Authorised
- Sponsor
- CHU Grenoble Alpes
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Escitalopram + prucalopride with Escitalopram + placebo (2 arms). Primary endpoint: Change in HDRS-21 from baseline to day 14. Planned start Sep 2025; status: authorised.
02
Drugs
prucaloprideescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-521811-38-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521811-38-01.